Reductive Surgery Plus Percutaneous Isolated Hepatic Perfusion for Multiple Advanced Hepatocellular Carcinoma

Overview

Journal Ann Surg

Specialty General Surgery

Date 2003 Dec 20

PMID 14685100

Citations 22

Authors

Yonson Ku

Takeshi Iwasaki

Masahiro Tominaga

Takumi Fukumoto

Tetsuya Takahashi

Masahiro Kido

Satoshi Ogata

Masanori Takahashi

Yoshikazu Kuroda

Shinichi Matsumoto

Hidefumi Obara

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the efficacy of a novel 2-stage treatment with reductive surgery plus percutaneous isolated hepatic perfusion (PIHP) for multiple hepatocellular carcinoma (HCC), which was previously unresectable.

Summary Background Data: Surgical resection is the treatment of choice for HCC, but the majority of patients with advanced HCC are not suitable candidates. PIHP is a minimally invasive surgery that allows high-dose regional chemotherapy of the liver, and our phase II studies have shown its profound efficacy for the local control of advanced HCC.

Methods: Twenty-five patients with multiple advanced HCC were enrolled in this prospective study. In the first stage, all patients underwent reductive hepatectomy: major hepatectomy in 13 patients and segmentectomy or less in 12. In 2 patients with subsegmentectomy, the retropancreatic and periportal metastatic lymph nodes were synchronously resected. Regardless of the type of hepatectomy, all patients routinely underwent cholecystectomy, and ligations of the right gastric artery and arterial collaterals of the remnant liver to increase the safety and efficacy of PIHP. In the second stage, PIHP with doxorubicin 60-120 mg/m2/treatment was planned for a period of 1 to 3 months after surgery.

Results: Of 25 enrolled patients, 22 successfully underwent PIHP an average of 1.8 times for the local control of residual liver tumors. In the remaining 3 patients, PIHP was abandoned because 2 had rapid disease progression and 1 had liver failure after surgery. In 22 patients with the 2-stage treatment, 19 (86%) had objective local tumor control (10 complete remissions and 9 partial responses with a median response duration of 16 months). The actuarial survival rate of all 25 patients was 42% at 5 years.

Conclusions: Reductive surgery plus PIHP produced a strong antitumoral effect on multiple advanced HCC, when liver function allows this concentrated treatment approach, and offers long-term survival in a subset of patients who were previously deemed to have unresectable disease.

Citing Articles

Innovative applications and research progress of hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma.

Yang T, Kong M World J Gastrointest Oncol. 2025; 17(2):99332.

PMID: 39958555 PMC: 11755998. DOI: 10.4251/wjgo.v17.i2.99332.

Peri-Interventional Hemodynamic Management Strategies for Percutaneous Chemosaturation of the Liver in Metastatic Cancer.

Rehn P, Tan B, Turra J, Adler P, Mayer P, Fischer D Cancers (Basel). 2024; 16(21).

PMID: 39518136 PMC: 11545105. DOI: 10.3390/cancers16213698.

Analysis of patient's X-ray exposure in hepatic chemosaturation procedures: a single center experience.

Ebel S, Reinhardt M, Beeskow A, Teske F, Struck M, Veelken R BMC Med Imaging. 2022; 22(1):165.

PMID: 36100850 PMC: 9469537. DOI: 10.1186/s12880-022-00887-2.

Impact of Hepatectomy for Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombus.

Komatsu S, Kido M, Kuramitsu K, Tsugawa D, Gon H, Fukushima K J Gastrointest Surg. 2021; 26(4):822-830.

PMID: 34716534 DOI: 10.1007/s11605-021-05181-0.

Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma.

Mondaca S, Yarmohammadi H, Kemeny N Surg Oncol Clin N Am. 2019; 28(4):717-729.

PMID: 31472915 PMC: 8240360. DOI: 10.1016/j.soc.2019.06.008.

References

Belghiti J, Panis Y, Farges O, Benhamou J, Fekete F . Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg. 1991; 214(2):114-7. PMC: 1358509. DOI: 10.1097/00000658-199108000-00004. View

Livraghi T, Bolondi L, Lazzaroni S, Marin G, Morabito A, Rapaccini G . Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer. 1992; 69(4):925-9. DOI: 10.1002/1097-0142(19920215)69:4<925::aid-cncr2820690415>3.0.co;2-g. View

Yamamoto M, Iizuka H, Matsuda M, Nagahori K, Miura K, Itakura J . The indications for tumor mass reduction surgery and subsequent multidisciplinary treatments in stage IV hepatocellular carcinoma. Surg Today. 1993; 23(8):675-81. DOI: 10.1007/BF00311704. View

Sasaki Y, Imaoka S, Masutani S, Ohashi I, Ishikawa O, Koyama H . Influence of coexisting cirrhosis on long-term prognosis after surgery in patients with hepatocellular carcinoma. Surgery. 1992; 112(3):515-21. View

Ku Y, Saitoh M, Nishiyama H, Fujiwara S, Iwasaki T, Tominaga M . Extracorporeal removal of anticancer drugs in hepatic artery infusion: the effect of direct hemoperfusion combined with venovenous bypass. Surgery. 1990; 107(3):273-81. View

Curley S, Izzo F, Delrio P, Ellis L, Granchi J, Vallone P . Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg. 1999; 230(1):1-8. PMC: 1420837. DOI: 10.1097/00000658-199907000-00001. View

Mor E, Tur-Kaspa R, Sheiner P, Schwartz M . Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med. 1998; 129(8):643-53. DOI: 10.7326/0003-4819-129-8-199810150-00013. View

Ku Y, Iwasaki T, Fukumoto T, Tominaga M, Muramatsu S, Kusunoki N . Induction of long-term remission in advanced hepatocellular carcinoma with percutaneous isolated liver chemoperfusion. Ann Surg. 1998; 227(4):519-26. PMC: 1191307. DOI: 10.1097/00000658-199804000-00012. View

Jiao L, Hansen P, Havlik R, Mitry R, Pignatelli M, Habib N . Clinical short-term results of radiofrequency ablation in primary and secondary liver tumors. Am J Surg. 1999; 177(4):303-6. DOI: 10.1016/s0002-9610(99)00043-4. View

10.

Hasegawa S, Yamasaki N, Hiwaki T, Sako K, Komorizono Y, Baba Y . Factors that predict intrahepatic recurrence of hepatocellular carcinoma in 81 patients initially treated by percutaneous ethanol injection. Cancer. 1999; 86(9):1682-90. DOI: 10.1002/(sici)1097-0142(19991101)86:9<1682::aid-cncr9>3.0.co;2-6. View

11.

Ku Y, Fukumoto T, Tominaga M, Iwasaki T, Maeda I, Kusunoki N . Single catheter technique of hepatic venous isolation and extracorporeal charcoal hemoperfusion for malignant liver tumors. Am J Surg. 1997; 173(2):103-9. DOI: 10.1016/S0002-9610(96)00422-9. View

12.

Hamazoe R, Hirooka Y, Ohtani S, Katoh T, Kaibara N . Intraoperative microwave tissue coagulation as treatment for patients with nonresectable hepatocellular carcinoma. Cancer. 1995; 75(3):794-800. DOI: 10.1002/1097-0142(19950201)75:3<794::aid-cncr2820750308>3.0.co;2-5. View

13.

Lin D, Lin S, Liaw Y . Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 1998; 12(9-10):S319-28. DOI: 10.1111/j.1440-1746.1997.tb00516.x. View

14.

Nagasue N, Uchida M, Makino Y, Takemoto Y, Yamanoi A, Hayashi T . Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology. 1993; 105(2):488-94. DOI: 10.1016/0016-5085(93)90724-q. View

15.

Miller A, Hoogstraten B, STAQUET M, Winkler A . Reporting results of cancer treatment. Cancer. 1981; 47(1):207-14. DOI: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. View

16.

Bismuth H, Houssin D, Ornowski J, Meriggi F . Liver resections in cirrhotic patients: a Western experience. World J Surg. 1986; 10(2):311-7. DOI: 10.1007/BF01658152. View

17.

. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg. 1990; 211(3):277-87. PMC: 1358432. View

18.

Shimada M, Takenaka K, Kawahara N, Kajiyama K, Yamamoto K, Shirabe K . Surgical treatment strategy for patients with stage IV hepatocellular carcinoma. Surgery. 1996; 119(5):517-22. DOI: 10.1016/s0039-6060(96)80260-1. View

19.

Curley S, Izzo F, Ellis L, Nicolas Vauthey J, Vallone P . Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg. 2000; 232(3):381-91. PMC: 1421151. DOI: 10.1097/00000658-200009000-00010. View

20.

Ku Y, Tominaga M, Iwasaki T, Fukumoto T, Muramatsu S, Kusunoki N . [The long-term results of percutaneous isolated hepatic perfusion for patients with advanced hepatocellular carcinoma]. Gan To Kagaku Ryoho. 1998; 25(9):1266-8. View